Sickle Cell Trait Runs Silent. Here's How to Know for Sure.

The HBB gene codes for beta-globin, one of the two protein chains that make up hemoglobin, the molecule inside red blood cells that carries oxygen. Normal hemoglobin is shaped like a smooth disc, flowing easily through blood vessels and delivering oxygen efficiently to every cell in your body.

The sickle cell mutation is a single-letter change in the HBB gene that swaps glutamic acid for valine at position 6 of the beta-globin protein. This tiny change causes hemoglobin molecules to polymerize, or stick together, under low oxygen conditions, transforming red blood cells into stiff, crescent or sickle shapes. Roughly 1 in 13 African Americans carries at least one copy of this mutation, as do significant populations from the Caribbean, Mediterranean, Middle East, and India. If you carry one copy, you’re a carrier and usually asymptomatic. If you inherit two copies (one from each parent), you have sickle cell disease.

Carriers often never know unless tested. You won’t feel sick, won’t have pain crises, and won’t see evidence on routine blood work. But if your partner is also a carrier, the genetics shift dramatically. Each child of two carriers has a 25% chance of inheriting two copies and having sickle cell disease.

BRCA1 is a tumor suppressor gene that produces a protein responsible for repairing breaks in DNA strands. When a cell is damaged, BRCA1 kicks in to fix the fracture, preventing cancer from developing. This gene acts as a guardian against uncontrolled cell growth.

Pathogenic variants in BRCA1 disable this repair function, allowing DNA damage to accumulate in cells over time. Roughly 1 in 400 people in the general population carry a pathogenic BRCA1 mutation, though rates are higher in Ashkenazi Jewish and certain other populations. People with BRCA1 variants have a 55-72% lifetime risk of developing breast cancer and elevated risk for ovarian, pancreatic, and other cancers.

If you carry a BRCA1 mutation, your cells are essentially fighting a losing battle against DNA damage. It doesn’t mean you will definitely get cancer, but it means your body has a significant disadvantage in preventing tumors. Knowing this status allows you to pursue intensive screening, preventive medications, or surgical interventions before disease develops.

BRCA2 is a partner to BRCA1 in the DNA repair team. It produces a protein that localizes BRCA1 to broken DNA strands and helps orchestrate the repair machinery. Together, they prevent mutations from becoming cancers.

Pathogenic BRCA2 variants impair this critical repair process, allowing DNA damage to persist and cells to transform into tumors. Roughly 1 in 800 people carry a pathogenic BRCA2 mutation, though Ashkenazi Jewish individuals have higher prevalence. People with BRCA2 mutations face a 45-69% lifetime breast cancer risk and significantly elevated risk for ovarian cancer, pancreatic cancer, and male breast cancer.

BRCA2 carriers experience the same slow accumulation of unrepaired DNA damage as BRCA1 carriers, but the mutation may manifest differently across tissues. Men with BRCA2 mutations also face elevated breast cancer risk, which catches many families off guard. Like BRCA1, BRCA2 carrier status transforms from an unknown into a concrete health plan.

MTHFR is a crucial enzyme that converts dietary folate (vitamin B9) into methylfolate, the active form your cells use to build DNA, repair damage, and regulate homocysteine, an amino acid linked to cardiovascular disease. Every cell in your body depends on this conversion happening smoothly.

The MTHFR C677T variant reduces enzyme activity by roughly 40-70% depending on whether you carry one or two copies. Approximately 40% of people with European ancestry carry at least one copy of C677T, making it one of the most common genetic variants in the population. The consequence is slow conversion of folate to methylfolate, causing folate to accumulate and usable methylfolate to remain scarce. Homocysteine often rises as a result.

You may notice this as low energy, brain fog, mood instability, or difficulty with focus and memory. Because methylation depends on MTHFR, slow variants also impair detoxification, neurotransmitter production, and immune function. A high-carb or low-folate diet makes symptoms worse. Standard blood tests usually miss the MTHFR variant unless specifically ordered, so many people remain functionally depleted without knowing why.

Factor V is a clotting protein that acts as a cofactor in the coagulation cascade, helping your blood form stable clots when you’re injured. Without it, you’d bleed uncontrollably from minor cuts. With it in balance, clots form when needed and dissolve when healing is done.

The Factor V Leiden variant (R506Q) impairs the body’s natural clot-dissolving mechanism, making clots harder to break down once formed. Roughly 5% of people with European ancestry carry the Leiden variant, and it increases venous thromboembolism risk (deep vein thrombosis and pulmonary embolism) by 4-8 times. That risk jumps to roughly 80 times higher if you also take oral contraceptives, and even higher in pregnancy.

Most carriers never have a clot. But if you’re a woman considering birth control pills, pregnant, or planning surgery, this mutation matters enormously. You might experience a calf clot, chest pain from a lung clot, or even fatal complications from thromboembolism when the genetics and triggers align. Knowing your F5 status allows your doctor to choose safer contraception, monitor you in pregnancy, or use blood thinners during surgery.

HLA-DQ2 is a human leukocyte antigen, a protein on the surface of immune cells that presents antigens (foreign proteins) to trigger immune responses. Your HLA genes determine which foreign molecules your immune system recognizes as dangerous and attacks. They’re crucial for distinguishing self from non-self.

HLA-DQ2 is present in roughly 30-40% of the general population, but it appears in 90-95% of people with celiac disease. When someone with HLA-DQ2 (or HLA-DQ8) eats gluten, their immune system mistakes gluten peptides for dangerous invaders and attacks the small intestine lining, causing inflammation, malabsorption, and intestinal damage.

Carrying HLA-DQ2 doesn’t guarantee you’ll develop celiac disease, but it’s a necessary genetic foundation for the condition. If you have unexplained digestive symptoms, anemia, fatigue, or autoimmune diseases, and you carry HLA-DQ2, celiac testing becomes urgent. If you don’t carry it, celiac disease is extremely unlikely and you can rule it out definitively.